Narrative updates are currently in beta.

Back to narrative

Update shared on04 Aug 2025

Fair value Increased 5.84%
AnalystConsensusTarget's Fair Value
₹3,276.68
0.6% undervalued intrinsic discount
08 Aug
₹3,256.00
Loading
1Y
-0.02%
7D
1.9%

The upward revision in Dr. Lal PathLabs’ consensus price target is primarily driven by improved revenue growth forecasts, while valuation multiples remain steady, resulting in the fair value increasing from ₹3,096 to ₹3,269.


What's in the News


  • Upcoming board meeting to consider and approve Q1 FY2025-26 unaudited standalone and consolidated financial results.
  • Board will also consider recommending an interim dividend on equity shares for FY2025-26.

Valuation Changes


Summary of Valuation Changes for Dr. Lal PathLabs

  • The Consensus Analyst Price Target has risen from ₹3096 to ₹3269.
  • The Consensus Revenue Growth forecasts for Dr. Lal PathLabs has risen from 11.6% per annum to 12.5% per annum.
  • The Future P/E for Dr. Lal PathLabs remained effectively unchanged, moving only marginally from 56.11x to 55.73x.

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.